Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

1. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials

Université de Paris and Department of Gastroenterology and Gastrointestinal Oncology, Georges-Pompidou European Hospital, Paris, France. 20 Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA. 21 Department of Health Science Research, Mayo Clinic, Rochester, MN, USA. Electronic address: shi.qian2@mayo.edu. PMID: 33271092 PMCID: PMC7786835 (available on 2021-12-01 ) DOI: Item in Clipboard Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA (...) Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set

2021 EvidenceUpdates

2. Endoscopic Recognition and Management Strategies for Malignant Colorectal Polyps: Recommendations of the US Multi-Society Task Force on Colorectal Cancer

, Narrow Band Imaging International Colorectal Endoscopic; OR, odds ratio; RR, relative risk; USMSTF, US Multi-Society Task Force on Colorectal Cancer. © 2020 by the American College of Gastroenterology, AGA Institute, and the American Society for Gastrointestinal Endoscopy. The American Journal of Gastroenterology: doi: 10.14309/ajg.0000000000001013 Free Metrics Colorectal polyps are the precursors for most colorectal cancers (CRCs). Some colorectal polyps accumulate enough mutations to develop high (...) most often raised by malignant polyps is whether a patient with an endoscopically resected colorectal lesion with submucosal invasion requires surgical resection of the colorectal segment from which the lesion was removed. Some malignant polyps can be managed endoscopically because the risk of residual cancer in the bowel wall and/or adjacent lymph nodes is very low. Other endoscopically resected malignant polyps are best managed by surgical resection because endoscopic resection alone

2021 American College of Gastroenterology

3. Pembrolizumab (Keytruda) as monotherapy for the first-line treatment of MSI H or dMMR colorectal cancer

Pembrolizumab (Keytruda) as monotherapy for the first-line treatment of MSI H or dMMR colorectal cancer Pembrolizumab (Keytruda®) as monotherapy for the first-line treatment of MSI H or dMMR colorectal cancer - Repository of AIHTA GmbH English | Browse - - - Pembrolizumab (Keytruda®) as monotherapy for the first-line treatment of MSI H or dMMR colorectal cancer Grössmann, N. (2020): Pembrolizumab (Keytruda®) as monotherapy for the first-line treatment of MSI H or dMMR colorectal cancer

2021 Austrian Institute of Health Technology Assessment

4. Intratumoural immune signature to identify patients with primary colorectal cancer who do not require follow-up after resection: an observational study Full Text available with Trip Pro

Intratumoural immune signature to identify patients with primary colorectal cancer who do not require follow-up after resection: an observational study Intratumoural immune signature to identify patients with primary colorectal cancer who do not require follow-up after resection: an observational study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose (...) a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This project was not successful in its aim due to failure to achieve a reliable cell counting system. {{author}} {{($index , , , , & . John N Primrose 1, * , Siân A Pugh 1, 2 , Gareth Thomas 1 , Matthew Ellis 1 , Karwan Moutasim 1, 3 , David Mant 4 1 Cancer Sciences Division, University of Southampton

2021 NIHR HTA programme

5. Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer

that were outstanding after the technical engagement stage. The condition The condition There is an unmet need for treatments for BRAF V600E There is an unmet need for treatments for BRAF V600E mutation-positive metastatic colorectal cancer mutation-positive metastatic colorectal cancer 3.1 Colorectal cancer is a malignant tumour arising from the lining of the large intestine (colon and rectum). BRAF is a human gene that encodes the protein B-Raf, which influences cell growth. Metastatic colorectal (...) Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer T echnology appraisal guidance Published: 6 January 2021 www.nice.org.uk/guidance/ta668 © NICE 2021. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations

2021 National Institute for Health and Clinical Excellence - Technology Appraisals

6. Endoscopic Recognition and Management Strategies for Malignant Colorectal Polyps: Recommendations of the US Multi-Society Task Force on Colorectal Cancer Full Text available with Trip Pro

of the submucosa, respectively. Kikuchi R. Takano M. Takagi K. et al. Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines. Dis Colon Rectum. 1995; 38 : 1286-1295 The Kikuchi classification system is presented in . The difficulty in implementing the Kikuchi system is that the entire submucosa is not typically present in endoscopic resection specimens. For that reason, the Kikuchi system has been largely replaced by measuring the depth of submucosal invasion with an optical (...) resection of the colorectal segment from which the lesion was removed. Some malignant polyps can be managed endoscopically because the risk of residual cancer in the bowel wall and/or adjacent lymph nodes is very low. Other endoscopically resected malignant polyps are best managed by surgical resection because endoscopic resection alone is accompanied by a very high risk of residual cancer and/or lymph node metastases. Optimal selection of patients with malignant polyps for endoscopic surveillance vs

2020 American Gastroenterological Association Institute

7. Randomized Controlled Trial of Personalized Colorectal Cancer Risk Assessment vs Education to Promote Screening Uptake

Randomized Controlled Trial of Personalized Colorectal Cancer Risk Assessment vs Education to Promote Screening Uptake Randomized Controlled Trial of Personalized Colorectal Cancer Risk Assessment vs Education to Promote Screening Uptake - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving (...) Controlled Trial of Personalized Colorectal Cancer Risk Assessment vs Education to Promote Screening Uptake , , , , , Affiliations Expand Affiliations 1 Department of Medicine, Stanford University School of Medicine, Stanford, California, USA. 2 Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA. 3 Division of Gastroenterology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA. 4 Division

2020 EvidenceUpdates

8. Analgesic Effect of Intrathecal Fentanyl vs Dexmedetomidine as Adjuvants to Bupivacaine Following Abdominal Surgery for Cancer in Children, a Randomized Trial

Analgesic Effect of Intrathecal Fentanyl vs Dexmedetomidine as Adjuvants to Bupivacaine Following Abdominal Surgery for Cancer in Children, a Randomized Trial Analgesic Effect of Intrathecal Fentanyl vs Dexmedetomidine as Adjuvants to Bupivacaine Following Abdominal Surgery for Cancer in Children, a Randomized Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) . 2020 Sep 11;pnaa259. doi: 10.1093/pm/pnaa259. Online ahead of print. Analgesic Effect of Intrathecal Fentanyl vs Dexmedetomidine as Adjuvants to Bupivacaine Following Abdominal Surgery for Cancer in Children, a Randomized Trial , , , , Affiliations Expand Affiliations 1 Anesthesia, Intensive Care and Pain Management, South Egypt Cancer Institute, Assiut University, Assiut, Egypt. 2 Pediatric Oncology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt. PMID: 32914161 DOI: Item

2020 EvidenceUpdates

9. AGA Clinical Practice Update on Young Adult Onset Colorectal Cancer Diagnosis and Management: Expert Review Full Text available with Trip Pro

in bowel habit, abdominal pain, iron deficiency anemia. Best Practice Advice 2 Clinicians should obtain family history of colorectal and other cancers in first and second degree relatives of patients with young adult–onset CRC and discuss genetic evaluation with germline genetic testing either in targeted genes based on phenotypic presentation or in multiplex gene panels regardless of family history. Best Practice Advice 3 Clinicians should present the role of fertility preservation prior to cancer (...) Lynch syndrome MSH2 Bailey C.E. Hu C.-Y. You Y.N. et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975–2010. JAMA Surg. 2015; 150 : 17-22 EPCAM Autosomal dominant Colorectal Endometrial Ovary Stomach Hepatobiliary Upper urinary tract Pancreas Small Bowel CNS (Glioblastoma) 49 (29–85) 57 (22–82) 20 (1–66) 11–19 2–7 4–5 3–4 1–4 1–3 Age 20–25 y: Colonoscopy every 1–2 y Flexible sigmoidoscopy every 1–2 y post-IRA Consider annual endometrial

2020 American Gastroenterological Association Institute

10. Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age

Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable (...) : 10.1053/j.gastro.2020.05.049. Epub 2020 May 20. Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age , , , , , , Affiliations Expand Affiliations 1 National Institute for Health Research Birmingham Biomedical Research Centre, Centre for Liver and Gastroenterology Research, University of Birmingham, Birmingham, United Kingdom; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United

2020 EvidenceUpdates

11. Identifying Features of Screening Approaches for People at Increased Risk of Colorectal Cancer

the guidelines when defining individuals at average CRC risk, which typically included those who are above the age of 50 years with no personal or family history of CRC, with no risk factors (e.g., hereditary syndromes such as familial adenomatous polyposis or Lynch syndrome), without a history of abdominal or pelvic radiation due to previous cancer, or a history of inflammatory bowel disease.(4-9) One guideline from 2017 by the US Multi-Society Task Force on Colorectal Cancer recommended that the African (...) of 60 • History of inflammatory bowel disease • Suspected or confirmed hereditary CRC syndrome • Suspected or confirmed history of abdominal or pelvic radiation • Family history and genetic counselling referrals for hereditary syndromes Identifying Features of Screening Approaches for People at Increased Risk for Colorectal Cancer 12 Evidence >> Insight >> Action Evidence source Document characteristics Average CRC risk Increased CRC risk Screening criteria Features of approaches for managing CRC

2020 McMaster Health Forum

12. Multicomponent Interventions to Improve Screening for Breast, Cervical or Colorectal Cancer

Multicomponent Interventions to Improve Screening for Breast, Cervical or Colorectal Cancer Oregon Health Authority : Evidence-based Reports Blog : Health Evidence Review Commission : State of Oregon menu Toggle Main Menu Main Navigation close search Search search Submit You are here: Evidence-based Reports Blog menu Site Navigation Evidence-based Reports Blog Full Width Column 1 Select Ablation for Atrial Fibrillation Acellular Dermal Matrix for Post-Mastectomy Breast Reconstruction Compliance (...) ={ListId}'); return false;} if(pageid == 'audit') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+ '/_layouts/15/Reporting.aspx' +'?Category=Auditing&backtype=item&ID={ItemId}&List={ListId}'); return false;} if(pageid == 'config') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+ '/_layouts/15/expirationconfig.aspx' +'?ID={ItemId}&List={ListId}'); return false;}}, null); 0x0 0x1 ContentType 0x01 898 BlogTopic Multicomponent Interventions to Improve Screening for Breast, Cervical or Colorectal Cancer

2020 Oregon Health Evidence Review Commission

13. Health Economic Studies of Colorectal Cancer and the Contribution of Administrative Data: a Systematic Review Full Text available with Trip Pro

Health Economic Studies of Colorectal Cancer and the Contribution of Administrative Data: a Systematic Review Health Economic Studies of Colorectal Cancer and the Contribution of Administrative Data: a Systematic Review | medRxiv Search for this keyword Health Economic Studies of Colorectal Cancer and the Contribution of Administrative Data: a Systematic Review Elizabeth Lemmon , Catherine Hanna , Peter S Hall , Eva Morris doi: https://doi.org/10.1101/2020.09.29.20203679 Elizabeth Lemmon 1 (...) University of Edinburgh; For correspondence: Catherine Hanna 2 University of Glasgow; For correspondence: Peter S Hall 1 University of Edinburgh; For correspondence: Eva Morris 3 University of Oxford For correspondence: Abstract Introduction: Several forces are contributing to an increase in the number of people living with and surviving colorectal cancer (CRC). However, due to the lack of available data, little is known about those implications. In recent years, the use of administrative records

2020 Cold Spring Harbor Laboratory

14. Exercise and colorectal cancer: a systematic review and meta-analysis of exercise safety, feasibility and effectiveness Full Text available with Trip Pro

in Colon Cancer patients undergoing chemotherapy. Med Sci Sports Exerc. 2016;48(5):767–75. 55. van Rooijen SJ, Engelen MA, Scheede-Bergdahl C, Carli F, Roumen RMH, Slooter GD, et al. Systematic review of exercise training in colorectal cancer patients during treatment. Scand J Med Sci Sports. 2018;28(2):360–70. 56. Spence R, DiSipio T, Schmitz K, Hayes S. Is unsupervised exercise following breast cancer safe for all women? Int J Phys Med Rehabil. 2014;2(197):1–8. 57. Cancer Research UK. Bowel Cancer (...) with adjuvant treatments include pain, weakness, fatigue, diarrhea, cardiotoxicity, bowel dysfunction, anorectal dysfunction, sexual dysfunction, anxiety, depression, reduced physical fitness and function, and reduced quality of life (QoL, [ , , , ]). Impairments in social and role functioning, particularly the ability to participate in community activities, social activities, and undertake work and employment have also been reported by colorectal cancer survivors [ ]. Further, more than 30% of patients

2020 International Journal of Behavioral Nutrition and Physical Activity

15. Prognosis Value of Low microRNA-34a Expression in Human Gastrointestinal Cancer: A Meta-Analysis Full Text available with Trip Pro

Prognosis Value of Low microRNA-34a Expression in Human Gastrointestinal Cancer: A Meta-Analysis Prognosis Value of Low microRNA-34a Expression in Human Gastrointestinal Cancer: A Meta-Analysis | Research Square Browse Tools & Services Your Cart See the published version of this article at . This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint (...) on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article Prognosis Value of Low microRNA-34a Expression in Human Gastrointestinal Cancer: A Meta-Analysis Yan-Ling Chen, Xiao-Lin Liu, Ling Li Yan-Ling Chen First Affiliated Hospital of Soochow University ORCiD: https://orcid.org/0000-0002-3196-1053 Xiao-Lin Liu The First Affiliated Hospital of Soochow University Corresponding Author

2020 Research Square

16. Variation rs9929218 and Risk of the Colorectal Cancer and Adenomas: A Meta-analysis Full Text available with Trip Pro

Variation rs9929218 and Risk of the Colorectal Cancer and Adenomas: A Meta-analysis Variation rs9929218 and Risk of the Colorectal Cancer and Adenomas: A Meta-analysis | Research Square Browse Tools & Services Your Cart This preprint is under consideration at BMC Cancer . A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should (...) not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article Variation rs9929218 and Risk of the Colorectal Cancer and Adenomas: A Meta-analysis Huiyan Wang, Dongying Gu, Miao Yu, Yanjun Hu, Zhe Chen, Xinying Huo, Tao Yu, Jinfei Chen, Yang Zheng Huiyan Wang Liaoning Cancer Institute and Hospital Dongying Gu Nanjing First Hospital Miao Yu Liaoning Cancer Institute and Hospital Yanjun Hu Liaoning Cancer Institute

2020 Research Square

17. Expert guidance on screening for colorectal and pancreatic cancer in BRCA1 and BRCA2 carriers

Expert guidance on screening for colorectal and pancreatic cancer in BRCA1 and BRCA2 carriers Expert guidance on screening for colorectal and pancreatic cancer in BRCA1 and BRCA2 carriers | American Gastroenterological Association Login here Gastro.org Gastro.org AGA Journals AGA Journals AGA’s peer-reviewed journals offer high-quality research on current advances in GI and hepatology. Access the latest research from Gastroenterology , Clinical Gastroenterology and Hepatology , Cellular (...) and Molecular Gastroenterology and Hepatology , and Techniques and Innovations in Gastrointestinal Endoscopy . AGA University AGA University AGA University is your home for in-person meetings, webinars and other educational tools designed to help you stay current with advances in the GI field and earn MOC/CME. AGA Research Foundation AGA Research Foundation The AGA Research Foundation funds young investigators who are committed to advancing gastroenterology. Through research, we can identify new treatment

2020 American Gastroenterological Association Institute

18. Efficacy and safety of traditional Chinese medicine decoction combined with chemotherapy in the treatment of advanced colorectal cancer A protocol of a systematic review and meta-analysis Full Text available with Trip Pro

Efficacy and safety of traditional Chinese medicine decoction combined with chemotherapy in the treatment of advanced colorectal cancer A protocol of a systematic review and meta-analysis Inplasy Protocol 700 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols

19. Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2020

389Introduction Colorectal cancer is one of the most common cancers world- wide, particularly in the economically developed world [1]. Large-bowel obstruction caused by advanced colonic cancer occurs in 8%–13% of colonic cancer patients [2–4]. The man- agementof thissevereclinicalconditionhasbeencontroversial [5].Over thelastdecade,manyarticleshavebeenpublishedon the subject of colonic stenting for malignant colonic obstruc- tion, including randomized controlled trials (RCTs) and sys- tematic reviews. Thereby (...) of metastasized colorectal cancer atdiagnosis[9].Colonoscopicnontraversability,i.e.,theinabil- itytoadvancethescopebeyondthetumor,hasbeensuggested as a risk factor for the development of symptomatic bowel ob- struction during treatment with primary chemotherapy [10– 12]. Nevertheless, prophylactic stenting for patients with colo- nicmalignancywithoutevidenceofsymptomaticobstructionis strongly discouraged because of the potential risks associated with colonic stenting. The only absolute contraindication

2020 European Society of Gastrointestinal Endoscopy

20. Localised Colon Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

or tests using other markers (e.g. M2-PK) lack formal comparisons of their performance, and integration with other assays needs to be monitored. Screening for high-risk populations is covered in the ESMO guidelines for hereditary gastrointestinal cancer [11]. DIAGNOSIS Symptoms and signs Colon cancer arises from the mucosa of the bowel, growing both into the lumen and the bowel wall, and/or spreading to adjacent organs. Symptoms are associated with relatively large tumours and/or advanced disease (...) screened and in case of inherited syndromes, also referred for genetic counselling (see ESMO guidelines for hereditary gastrointestinal cancer [11]): ? a medical history of adenoma, colon cancer, inflammatory bowel disease (Crohn’s disease and ulcerative colitis); ? significant family history of CRC or adenoma; 4 ? an inherited cancer syndrome (2%–5% of all CRC), such as familial adenomatous polyposis coli and its variants (1%), Lynch-associated syndromes (hereditary non-polyposis colon cancer) (2%–4

2020 European Society for Medical Oncology